Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY ISSUE OF JUNE 09, 2011 FBO #3484
SOLICITATION NOTICE

68 -- Manufacture of the Drug Tariquidar in Oral Formulation for Human Use

Notice Date
6/7/2011
 
Notice Type
Presolicitation
 
NAICS
325998 — All Other Miscellaneous Chemical Product and Preparation Manufacturing
 
Contracting Office
Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, Station Support/Simplified Acquisitions, 31 Center Drive, Room 1B59, Bethesda, Maryland, 20892
 
ZIP Code
20892
 
Solicitation Number
NOI-2124915
 
Archive Date
6/29/2011
 
Point of Contact
Korriise L. LaRoche, Phone: 301-435-8782
 
E-Mail Address
larochek@mail.nih.gov
(larochek@mail.nih.gov)
 
Small Business Set-Aside
N/A
 
Description
This is a notice of intent, not a request for a proposal. A solicitation document will not be issued and proposals will not be requested. The National Institute on Drug Abuse, Office of Acquisitions-Neuroscience, Station Support/Simplified Acquisition (SS/SA) on behalf of the National Institute of Mental Health (NIMH) intends to negotiate and award a purchase order on a sole source, noncompetitive basis to Avaant Pharmaceuticals, Inc., 35 Corporate Drive, Burlington, MA 01803-4223 for the purchase of the drug, tariquidar, which will be administered to human subjects. NIMH’s Molecular Imaging Branch Laboratory has studied tariquidar in human subjects for about four years. The Laboratory initially used an intravenous formulation of the drug, however it was difficult to dilute and required relatively large volumes of fluid for injection. To avoid the large volumes of intravenous fluid, the Laboratory changed about 1.5 years ago to an oral formulation. The drug is now administered by mouth as a capsule. Avaant Pharmaceuticals, Inc. is the sole manufacturer of the drug, tariquidar, for use in human subjects. They hold the world-wide license for this drug, as well as the Drug Master File for its manufacture. The acquisition is being conducted under FAR Part 12-Acquisition for Commercial Items and will be made pursuant to the authority of FAR 13.106-1(b)(2) and FAR 13.501(a)(1) to use Simplified Acquisition Procedures for Commercial Items. This is not a solicitation for competitive quotations. Interested parties may identify their interest and capabilities in response to this synopsis by submitting a statement of capabilities on or before 10:00 AM E.T., June 14, 2011 to Korriise LaRoche, larochek@mail.nih.gov. All information furnished must be in writing and must contain sufficient detail to allow the NIDA/NIMH to determine if it can meet the above unique specifications described herein. The determination by the Government not to compete the proposed contract based upon responses to this notice is solely with the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award from the NIDA, the vendor must be registered in the Online Representations and Certifications Applications (ORCA) at http://orca.bpn.gov. In addition, the vendor must be registered in the Central Contractor Registration (CCR) at ww.ccr.gov. Please reference announcement number NOI-2124915 on all correspondence.
 
Web Link
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-2/NOI-2124915/listing.html)
 
Record
SN02465987-W 20110609/110607234816-acec3006253a881ef3158d1931129057 (fbodaily.com)
 
Source
FedBizOpps Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.